vs
Side-by-side financial comparison of TOOTSIE ROLL INDUSTRIES INC (TR) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
TOOTSIE ROLL INDUSTRIES INC is the larger business by last-quarter revenue ($196.3M vs $103.7M, roughly 1.9× Twist Bioscience Corp). TOOTSIE ROLL INDUSTRIES INC runs the higher net margin — 14.7% vs -29.4%, a 44.1% gap on every dollar of revenue. On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs 1.5%). TOOTSIE ROLL INDUSTRIES INC produced more free cash flow last quarter ($61.0M vs $-34.8M).
Tootsie Roll Industries is an American manufacturer of confectionery based in Chicago, Illinois. Its best-known products include the namesake Tootsie Rolls and Tootsie Pops. Tootsie Roll Industries currently markets its brands internationally in Canada, Mexico, and over 75 other countries.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
TR vs TWST — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $196.3M | $103.7M |
| Net Profit | $28.8M | $-30.5M |
| Gross Margin | 35.7% | 52.0% |
| Operating Margin | 17.0% | -31.7% |
| Net Margin | 14.7% | -29.4% |
| Revenue YoY | 1.5% | 16.9% |
| Net Profit YoY | 27.9% | 3.4% |
| EPS (diluted) | — | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.3M | $103.7M | ||
| Q3 25 | $232.7M | — | ||
| Q2 25 | $155.1M | — | ||
| Q1 25 | $148.5M | — | ||
| Q4 24 | $193.4M | — | ||
| Q3 24 | $225.9M | — | ||
| Q2 24 | $150.7M | — | ||
| Q1 24 | $153.2M | — |
| Q4 25 | $28.8M | $-30.5M | ||
| Q3 25 | $35.7M | — | ||
| Q2 25 | $17.5M | — | ||
| Q1 25 | $18.1M | — | ||
| Q4 24 | $22.5M | — | ||
| Q3 24 | $32.8M | — | ||
| Q2 24 | $15.6M | — | ||
| Q1 24 | $15.8M | — |
| Q4 25 | 35.7% | 52.0% | ||
| Q3 25 | 34.1% | — | ||
| Q2 25 | 36.4% | — | ||
| Q1 25 | 35.3% | — | ||
| Q4 24 | 39.1% | — | ||
| Q3 24 | 34.1% | — | ||
| Q2 24 | 33.5% | — | ||
| Q1 24 | 32.7% | — |
| Q4 25 | 17.0% | -31.7% | ||
| Q3 25 | 13.9% | — | ||
| Q2 25 | 7.8% | — | ||
| Q1 25 | 15.5% | — | ||
| Q4 24 | 20.0% | — | ||
| Q3 24 | 15.6% | — | ||
| Q2 24 | 10.2% | — | ||
| Q1 24 | 7.3% | — |
| Q4 25 | 14.7% | -29.4% | ||
| Q3 25 | 15.3% | — | ||
| Q2 25 | 11.3% | — | ||
| Q1 25 | 12.2% | — | ||
| Q4 24 | 11.6% | — | ||
| Q3 24 | 14.5% | — | ||
| Q2 24 | 10.4% | — | ||
| Q1 24 | 10.3% | — |
| Q4 25 | — | $-0.50 | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $176.6M | $197.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $941.0M | $456.1M |
| Total Assets | $1.3B | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $176.6M | $197.9M | ||
| Q3 25 | $119.8M | — | ||
| Q2 25 | $170.5M | — | ||
| Q1 25 | $176.6M | — | ||
| Q4 24 | $194.6M | — | ||
| Q3 24 | $163.2M | — | ||
| Q2 24 | $131.2M | — | ||
| Q1 24 | $159.4M | — |
| Q4 25 | $941.0M | $456.1M | ||
| Q3 25 | $918.9M | — | ||
| Q2 25 | $893.1M | — | ||
| Q1 25 | $879.4M | — | ||
| Q4 24 | $870.7M | — | ||
| Q3 24 | $870.2M | — | ||
| Q2 24 | $841.4M | — | ||
| Q1 24 | $834.4M | — |
| Q4 25 | $1.3B | $638.1M | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $1.1B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $73.3M | $-24.8M |
| Free Cash FlowOCF − Capex | $61.0M | $-34.8M |
| FCF MarginFCF / Revenue | 31.1% | -33.5% |
| Capex IntensityCapex / Revenue | 6.3% | 9.6% |
| Cash ConversionOCF / Net Profit | 2.55× | — |
| TTM Free Cash FlowTrailing 4 quarters | $96.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $73.3M | $-24.8M | ||
| Q3 25 | $62.2M | — | ||
| Q2 25 | $-8.5M | — | ||
| Q1 25 | $3.6M | — | ||
| Q4 24 | $68.8M | — | ||
| Q3 24 | $61.3M | — | ||
| Q2 24 | $-12.6M | — | ||
| Q1 24 | $21.4M | — |
| Q4 25 | $61.0M | $-34.8M | ||
| Q3 25 | $50.7M | — | ||
| Q2 25 | $-16.0M | — | ||
| Q1 25 | $750.0K | — | ||
| Q4 24 | $64.7M | — | ||
| Q3 24 | $55.8M | — | ||
| Q2 24 | $-16.6M | — | ||
| Q1 24 | $16.9M | — |
| Q4 25 | 31.1% | -33.5% | ||
| Q3 25 | 21.8% | — | ||
| Q2 25 | -10.3% | — | ||
| Q1 25 | 0.5% | — | ||
| Q4 24 | 33.5% | — | ||
| Q3 24 | 24.7% | — | ||
| Q2 24 | -11.0% | — | ||
| Q1 24 | 11.0% | — |
| Q4 25 | 6.3% | 9.6% | ||
| Q3 25 | 5.0% | — | ||
| Q2 25 | 4.8% | — | ||
| Q1 25 | 1.9% | — | ||
| Q4 24 | 2.1% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 2.6% | — | ||
| Q1 24 | 2.9% | — |
| Q4 25 | 2.55× | — | ||
| Q3 25 | 1.74× | — | ||
| Q2 25 | -0.49× | — | ||
| Q1 25 | 0.20× | — | ||
| Q4 24 | 3.06× | — | ||
| Q3 24 | 1.87× | — | ||
| Q2 24 | -0.81× | — | ||
| Q1 24 | 1.35× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TR
| Products | $194.3M | 99% |
| Rental And Royalty | $1.9M | 1% |
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
